World Sleep Industry ENCYCLOPEDIA

HLA-related sleep disorder tests

2.2.1

Name, scope, and neighboring tests

HLA-related sleep disorder testing means laboratory typing of loci, alleles, or haplotypes in the human leukocyte antigen system and evaluation of their association with a defined sleep-disorder phenotype. This category concerns how HLA typing may answer a sleep-medicine question. It is not a sleep study that measures sleep duration, electroencephalographic stages, respiratory events, or daytime alertness, and it is not an ordinary immunoassay that uses antibodies to detect HLA protein. Placement under point testing and biomarker screening in this catalogue does not mean that current HLA assays necessarily produce a bedside result.

The most concentrated evidence and most frequently discussed clinical example is the association of HLA-DQB1*06:02 with narcolepsy, particularly narcolepsy type 1. Narcolepsy-related genetic testing can additionally encompass non-HLA susceptibility loci or investigational polygenic information; this entry is restricted to the HLA system. Solid-organ or hematopoietic-stem-cell matching, kinship analysis, HLA antibody screening, and pharmacogenomic testing for severe drug reactions may also involve HLA, but their purpose, validation requirements, and interpretive pathways differ. A sleep-disease association report cannot substitute for any of them.

HLA biology, nomenclature, and resolution

HLA comprises a highly polymorphic group of genes within the major histocompatibility complex. The encoded molecules participate in antigen presentation and immune recognition. An allele name normally contains the locus, an asterisk, and numerical fields separated by colons, as in HLA-DQB106:02. The first numerical field denotes an allele group, while later fields successively distinguish protein sequence, synonymous coding differences, and noncoding differences. A report of DQB106 does not contain the same information as DQB1*06:02, and an older serologic designation should not be treated mechanically as a current DNA allele name.

At a locus, a person generally inherits one allele from each parent. Neighboring HLA loci may be transmitted together because of linkage disequilibrium, producing haplotypes whose frequencies differ across populations. Signals at DQA1, DQB1, and DRB1 may therefore be correlated rather than representing several independent disease effects. Low-resolution typing may identify only an allele group; higher resolution can distinguish a more specific sequence. When the defined question is simply whether DQB1*06:02 is present, broad typing across many loci does not necessarily add clinical value and may instead generate findings unrelated to the original question.

Sleep-disorder associations and levels of evidence

HLA-DQB106:02 is markedly enriched among people with narcolepsy type 1 and is often observed with linked backgrounds such as DRB115:01 and DQA1*01:02. This association supports immune susceptibility, but it does not mean that every carrier will lose hypocretin-producing neurons. Many unaffected people carry an associated allele, a small minority of otherwise typical patients are negative, and the association is weaker in narcolepsy type 2. A genetic result can therefore modify likelihood in a defined setting; it cannot turn an immune association into proof of causation.

Research also explores population associations between HLA and REM sleep behavior disorder, sleep-related breathing disorders, restless legs syndrome, insomnia, idiopathic hypersomnia, or other phenotypes. Such findings can be affected by sample size, ancestry structure, diagnostic definitions, multiple comparisons, and replication. A single case-control association, database signal, or unreplicated allele finding is insufficient to establish a clinical screening service. Outside specific supporting use in narcolepsy, investigational HLA associations must not be expanded into a “one blood sample screens for many sleep disorders” claim, and one positive allele must not be used to explain biologically different diseases.

Specimens, typing technology, and quality control

Clinical typing most often extracts DNA from anticoagulated whole blood, although a particular laboratory may validate buccal swabs or saliva. Targeted assays may use sequence-specific primer or probe amplification, and broader typing may use sequencing. Array tag variants and statistical imputation instead infer an HLA type from correlated markers. Direct observation of a target sequence, inference through a proxy, and third-party interpretation of consumer raw data are not equivalent. Accuracy of an imputation can also change with the ancestry reference panel.

The process from collection to reporting needs controls for identity, container and transport, DNA quantity and purity, contamination, amplification failure, allele dropout, positive and negative controls, repeatability, and software version. The HLA region is complex, and reads may fit multiple combinations; a laboratory needs validated rules for ambiguity, rare alleles, and novel sequences. “Not detected” in a report must refer to a defined target and coverage. Sample failure, an uncovered locus, or inadequate resolution must not be rewritten as a true negative. Clinical use also requires appropriate laboratory qualification, method validation, and a defined intended population, not merely a colored risk category.

Result interpretation and population differences

Interpretation starts with the pretest question: what symptoms are present, which disorder is being considered, why this locus was selected, and whether a positive or negative answer will change the next step. A positive finding means that the reported HLA allele or combination was detected. It does not establish current disease and cannot, by itself, predict age at onset, severity, or response to treatment. A negative finding excludes only a target detectable within that method’s coverage; it neither excludes every HLA-related variation nor rules out disease cases that do not depend on that marker.

Sensitivity, specificity, likelihood ratios, and predictive values are not portable labels detached from population. Allele frequency, linkage structure, and baseline disease risk differ with ancestry and geography. Whether cases have type 1 or type 2 narcolepsy, whether cataplexy is typical, and which diagnostic standard a study used also change the value of a result. Directly calling a research odds ratio an individual “probability of disease,” adding the effects of two linked alleles, or treating the count of positive markers as disease dose is misleading. For mixed ancestry or an underrepresented reference population, uncertainty should be stated rather than forcing one population’s threshold onto the result.

Clinical position and tests it cannot replace

For suspected narcolepsy, the core remains a history of difficult-to-resist daytime sleepiness, cataplexy, and associated features, together with documentation of sufficient sleep and a stable schedule, a medication and substance review, and exclusion of insufficient sleep, circadian misalignment, sleep-disordered breathing, and other neurological or psychiatric explanations. Properly prepared attended overnight polysomnography followed by a multiple sleep latency test, and cerebrospinal-fluid hypocretin measurement in selected cases, answer questions different from HLA typing. An HLA result cannot replace these investigations or repair a sleep test confounded by inadequate preparation or medication effects.

An asymptomatic person generally cannot use an HLA result to determine whether disease will develop, and a positive result in a relative does not mean that family members require treatment or restrictions on education, occupation, or driving. For other sleep disorders, snoring and observed apneas require an appropriate sleep-breathing evaluation; dream enactment requires history and polysomnographic confirmation of REM sleep without atonia; restless legs syndrome remains a clinical diagnosis with assessment of associated factors. HLA typing is not a shortcut through these pathways and cannot direct unsupervised initiation, withdrawal, or selection of wake-promoting, sedating, or other treatment.

Service selection, report governance, and follow-up

Before ordering, confirm the purpose, target locus and allele, typing resolution, specimen, method, failure and repeat rules, intended population, turnaround, and cost. A useful report should identify the person and specimen, use current HLA nomenclature, state the detected result, coverage and resolution, interpretive basis, limitations, authorizing professional, and issue date. A report that merely says “high risk of a sleep disorder” without the locus, method, and reference population is inadequate for medical decisions. Older or truncated names need standardized mapping before reports are compared.

HLA information is enduring and may reveal genetic information shared with relatives. Consent should address residual specimen storage, secondary data use, cross-border transfer, third-party sharing, the practical ability to withdraw or delete data, and the applicable local employment, insurance, and privacy rules. Positive, negative, or discordant results should be reviewed from the original report with the phenotype by sleep-medicine, medical-genetics, or genetic-counseling professionals. Repeat testing, greater resolution, or additional loci have practical value only when they resolve a defined ambiguity and can change management.